Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple Sclerosis

🔗 Access full article via JAMA Neurology

This randomized clinical trial investigates whether first-line disease-modifying therapy can be safely discontinued in patients with long-term stable multiple sclerosis.